Last updated 2026-06-18
- Acquired by Ayala Pharmaceuticals, Oct 2023
- Raised $27M funding round led by Israel Biotech Fund, Dec 2020
- Raised $19M funding round led by Israel Biotech Fund, Mar 2020
Total raised
$62.5M
Last: 2020-12
Stage
Acquired
Founded
1999
Headcount
5
HQ
Lod
Sector
Health Tech & Life Sciences
About
Biosight is a phase-2 clinical-stage biotechnology company developing therapeutics for Hematological Malignancies and disorders.
Biosight's lead product, BST-236 (INN aspacytarabine), is a proprietary anti-metabolite designed to enable high-dose therapy with reduced systemic toxicity. BST-236 is currently being investigated as a single agent in a phase-2b trial for first-line treatment of acute myeloid leukemia (AML), following a successful and encouraging phase-1/2a trial, which demonstrated tolerability with promising efficacy in AML patients unfit for standard therapy.
Funding history · 5 rounds · $62.5M total
2020-12
2020-03
2008-07
$3.5M
2007-01
Undisclosed
Q&A
- What is BioSight's current status?
- BioSight was acquired by Ayala Pharmaceuticals in October 2023 and is currently inactive.
- What is BioSight's primary product?
- BioSight's lead product is BST-236 (INN aspacytarabine), a proprietary anti-metabolite for treating hematological malignancies and disorders.
- When did BioSight last raise funding and who were the lead investors?
- BioSight's last funding round was in December 2020, raising $27,000,000. Israel Biotech Fund was a lead investor.
- What was a significant clinical development for BioSight in November 2022?
- In November 2022, BioSight launched a Phase 1/2 clinical trial for aspacytarabine (BST-236) in combination with venetoclax for first-line Acute Myeloid Leukemia (AML) induction therapy.
- Did BioSight receive any special designations for BST-236 from the FDA?
- Yes, in June 2019, BioSight received Orphan Drug Designation from the FDA for BST-236 for the treatment of acute myeloid leukemia. In August 2020, it also received U.S. FDA Fast Track Designation for BST-236 for treating AML in specific adult patient populations.
- What was a key partnership announced by BioSight in July 2020?
- In July 2020, BioSight announced a clinical trial collaboration with the European Cooperative Group, Groupe Francophone des Myélodysplasies, to evaluate BST-236 as a second-line treatment for patients with relapsed or refractory Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML).
- When was BioSight founded and what is its employee count?
- BioSight was founded in November 1999 and has an employee count in the 1-10 range.
- Who are the co-founders of BioSight?
- The co-founders of BioSight are Stela Gengrinovitch, PhD, and Mark Gengrinovitch.
Team · 2
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
BiologicalsCells
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business model
B2B
Highlights
1 Patents
Tags
chemotherapycancerdrug-discoverybiopharmaceuticaltargeted-therapypharmaceuticalscancer-therapyoncologyhematology
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| linkedin.com/company/9423263 |
Identifiers & details
| Founded | 1999-11 |
|---|---|
| Employees (exact) | 5 |
| Status reason | Acquired (Inactive) by Ayala Pharmaceuticals on Oct 2023 - closed due to acquisition |
Acquisitions & public offerings
Acquired by Ayala Pharmaceuticals 2023-10
Radar intelligence
Patents
| EPO | 16 |
|---|
Publications (Crossref)
| Works | 10 |
|---|